Measuring Hope and Hopelessness in Cancer

Advanced Cancer Clinical Trial

Official title:

Measuring Hope and Hopelessness in Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00581880
• Other study ID #: 04-145
• Status: Completed
• Phase: N/A
• First received: December 21, 2007
• Last updated: January 14, 2009
• Start date: January 2005
• Est. completion date: January 2009

Study information

• Verified date: January 2009
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to develop an accurate and useful way of measuring patients' thoughts and feelings about hope and hopelessness as they relate to their illness. Doctors and psychologists from Memorial Sloan-Kettering Cancer Center, Calvary Hospital, the Peter MacCallum Cancer Centre, and Fordham University are working together to design a new measure. Findings from this research will help us study the nature of illness and develop improved methods of diagnosis and treatment. We hope what we learn from you will help us learn more about how to care better for patients with cancer and other severe illnesses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 288
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older.

• Patients who are able to understand verbal and written English.

• Diagnosis of cancer.

• Patients with advanced cancer receiving ambulatory or inpatient care at Memorial Sloan-Kettering Cancer Center in New York City. Patients at Calvary Hospital and Peter MacCallum Cancer Centre admitted for palliative care will also be eligible for participation in this study

Exclusion Criteria:

• The presence of a psychotic mental disorder (e.g., Bipolar Disorder, Schizophrenia, Schizo-affective illness, psychosis due to substance abuse) as indicated in medical chart.

• Cognitive impairment so severe (i.e., Mini-Mental State exam score of less than 20) that, in the opinion of the Principal Investigator or Project Coordinator, would interfere with a patient's ability to give informed consent for research.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Advanced Cancer

Intervention

Behavioral:
• questionnaires
A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Calvary Hospital, Bronx, NY, Fordham University, Peter MacCallum Cancer Centre, Australia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To explore and better understand the construct of hopelessness as it applies to terminally ill cancer patients.		conclusion of study	No
Primary	To develop a brief self-report measure of hopelessness grounded in the construct of hopelessness as it applies to terminally ill cancer patients.		conclusion of study	No
Secondary	To establish the reliability and validity of this newly developed measure of hopelessness in a large sample of terminally ill cancer patients.		conclusion of study	No

External Links

•   Memorial Sloan-Kettering Cancer Center